Company Encyclopedia
View More
name
Harvard Bioscience
HBIO.US
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States, Germany, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems.
770.89 B
HBIO.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
Life Sciences Tools and ServicesIndustry
Industry Ranking55/60
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-135.62%E
    • Profit Margin-61.62%E
    • Gross Margin58.38%B
  • Growth ScoreE
    • Revenue YoY-10.60%D
    • Net Profit YoY-278.03%E
    • Total Assets YoY-40.57%E
    • Net Assets YoY-78.46%E
  • Cash ScoreD
    • Cash Flow Margin-162.29%D
    • OCF YoY-10.60%D
  • Operating ScoreB
    • Turnover0.84B
  • Debt ScoreE
    • Gearing Ratio81.96%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Harvard Bioscience’s Earnings Call: Optimism Amid Challenges

    Harvard Bioscience (HBIO) held its Q3 earnings call, revealing a mix of optimism and caution. The company reported Q3 2025 revenue of $20.6 million, slightly down from $22 million in Q3 2024, but above guidance. Operational improvements led to a rise in adjusted EBITDA to $2 million, and a strong backlog was noted. However, challenges in the Chinese market and potential impacts from a U.S. government shutdown were highlighted. Looking ahead, Q4 revenue is expected between $22.5 million and $24.5 million, with gross margins projected at 58-60%.

    Tip Ranks·
    US
    HBIO
    -0.65%
    Tip Ranks·
    US
    HBIO
    -0.65%

    Benchmark Co. Keeps Their Buy Rating on Harvard Bioscience (HBIO)

    Benchmark Co. analyst Bruce Jackson has maintained a Buy rating on Harvard Bioscience (HBIO) with a price target of $2.00. The consensus among analysts is a Moderate Buy, also with a $2.00 target. Jackson, who covers the Healthcare sector, has an average return of -11.2% and a 35.29% success rate on his stock recommendations.

    Tip Ranks·
    US
    HBIO
    -0.65%
    Tip Ranks·
    US
    HBIO
    -0.65%

    Harvard Bioscience | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 20.59 M

    LB filings·
    US
    HBIO
    -0.65%
    LB filings·
    US
    HBIO
    -0.65%

    Harvard Bioscience | 8-K: FY2025 Q3 Revenue Beats Estimate at USD 20.59 M

    LB filings·
    US
    HBIO
    -0.65%
    LB filings·
    US
    HBIO
    -0.65%

    Harvard Bioscience Reports Q3 Revenue of $20.6 Million and Net Loss of $1.2 Million

    Harvard Bioscience Inc. reported Q3 2025 revenues of $20.6 million with a gross margin of 58.4%, alongside a net loss of $1.2 million. The company generated positive cash from operations and anticipates refinancing or repaying its debt in Q4. Guidance for Q4 2025 indicates increased demand and improved operations. Harvard Bioscience specializes in technologies for life science applications, serving various sectors globally.

    Reuters·
    US
    HBIO
    -0.65%
    Reuters·
    US
    HBIO
    -0.65%
    © 2025 Longbridge｜Disclaimer